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Abstract
 
The Non-Steroidal Anti-Inflammatory drug (NSAID) meloxicam has been deemed a 
safe and effective treatment for numerous inflammatory conditions and injuries from 
extensive pharmacokinetic and pharmacodynamic studies in various mammalian species. 
However, there is a lack of meloxicam pharmacokinetic information in avian species. This 
leads to pharmacokinetic data being extrapolated from mammals in order to administer 
and treat birds.  This often leads to ineffective pain relief or overdoses that can be fatal for 
birds. Due to this void in literature this study was designed to increase the basic 
pharmacokinetic knowledge in birds but to also determine if age affects the 
pharmacokinetics of meloxicam in ISA Brown chickens. Meloxicam was injected 
intravenously (IV) at 2 mg/kg in 20 healthy ISA Brown chickens (Gallus gallus domesticus). 
One group consisted of 10 ISA brown chickens that were 18 weeks old, the second group 
consisted of 10 ISA Brown chickens that were 24 months old. Serial blood samples were 
withdrawn from a catheterised vein from each ISA Brown chicken into a heparinised vial at 
0, 10, 20, 30 minutes, 1, 4, 8, 10, 12 hours after the administration of meloxicam. 
 
The pharmacokinetics for ISA Brown chickens were calculated using the non-
compartmental model, which was analysed using the mean data from each group of ISA Brown 
II 
 
chickens. The elimination half-life, steady state volume of distribution and mean resident time were 
significantly higher in the 24 month old ISB Brown chickens compared to the 18 week old ISA Brown 
chickens. Overall, the results indicate that as an ISA Brown chicken ages the pharmacokinetics of 
meloxicam show some significant changes in crucial pharmacokinetic parameters. The differences 
in the pharmacokinetic parameters may ultimately affect the efficacy of meloxicam when treating 
‘geriatric’ birds due to possible age-related health issues in the liver and kidneys, which are major 
organs involved in processing drugs.    
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